Welcome to our dedicated page for Sagimet Biosciences news (Ticker: SGMT), a resource for investors and traders seeking the latest updates and insights on Sagimet Biosciences stock.
Sagimet Biosciences Inc. (NASDAQ: SGMT) is a clinical-stage biopharmaceutical company developing oral fatty acid synthase (FASN) inhibitors for metabolic and fibrotic diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH) and moderate to severe acne. The news flow around SGMT reflects its progress in clinical development, licensing collaborations, and capital markets activity.
Company announcements frequently highlight clinical trial milestones for its lead candidate denifanstat, including results from the Phase 2b FASCINATE-2 trial in MASH and Phase 3 acne data generated by its license partner in China. News items also cover secondary analyses using AI-based digital pathology and spatial computational histology to characterize fibrosis and treatment response in advanced MASH, as well as updates on a Phase 1 pharmacokinetic trial combining denifanstat with the thyroid hormone receptor beta agonist resmetirom.
Investors following SGMT news can also expect updates on Sagimet’s second oral FASN inhibitor, TVB-3567, which is in a Phase 1 first-in-human trial and is planned for acne development. Additional coverage includes regulatory interactions such as China’s National Medical Products Administration acceptance of a New Drug Application for denifanstat (ASC40) in acne, and Sagimet’s own disclosures about Breakthrough Therapy designation and end-of-Phase 2 interactions for denifanstat in MASH.
Beyond clinical and regulatory developments, Sagimet issues news on its license agreement with TAPI for innovative forms of resmetirom API to support a fixed-dose combination program, participation in healthcare and liver disease conferences, and periodic financial and corporate updates reported via Form 8-K. This news page aggregates those press releases and related items so readers can track the evolution of Sagimet’s FASN inhibitor pipeline and key events affecting SGMT stock.
Sagimet Biosciences presented promising data from the Phase 2b FASCINATE-2 clinical trial of denifanstat at EASL 2024. Denifanstat significantly improved liver fibrosis and MASH resolution in patients with metabolic dysfunction-associated steatohepatitis (MASH), achieving primary and secondary endpoints.
Key results: 38% of denifanstat patients had a ≥2-point reduction in NAS without worsening fibrosis, compared to 16% for placebo. For fibrosis improvement by ≥1 stage without worsening MASH, results were 30% for denifanstat vs 14% for placebo. Denifanstat was well tolerated with no serious adverse events.
Based on these findings, Sagimet plans to initiate a Phase 3 registrational program for denifanstat in MASH with fibrosis in the latter half of 2024.
Sagimet Biosciences (Nasdaq: SGMT), a clinical-stage biopharmaceutical company, will host a virtual investor and analyst day on May 23, 2024, at 1:00 PM ET.
The event will feature Dr. Scott Friedman from Icahn School of Medicine at Mount Sinai, who will discuss the unmet needs and treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH). Additionally, the event will cover topline data from Sagimet's FASCINATE-2 Phase 2b clinical trial for its lead drug candidate, denifanstat, an oral FASN inhibitor. A live Q&A session will follow the presentation.
Sagimet Biosciences (Nasdaq: SGMT) reported its Q1 2024 financial results, highlighting significant progress in the development of denifanstat for metabolic dysfunction-associated steatohepatitis (MASH). The company announced positive results from the Phase 2b FASCINATE-2 trial, meeting primary efficacy endpoints and demonstrating significant fibrosis reduction. Full trial results will be presented at the EASL Congress in June 2024. Sagimet plans a Phase 3 trial following an FDA meeting in Q2 2024. The company raised $104.7 million from a public offering and holds $193.7 million in cash as of March 31, 2024, ensuring a cash runway through 2025. Research and development expenses increased to $5.3 million, while net losses remained consistent at $6.6 million year-over-year.
Sagimet Biosciences Inc. announced the oral presentation of denifanstat Phase 2b FASCINATE-2 study data at the EASL International Liver Congress 2024. The study demonstrated significant fibrosis improvement and MASH resolution in patients with F2 or F3 fibrosis.
Sagimet Biosciences Inc. announced the appointment of Thierry Chauche as Chief Financial Officer. Chauche brings over 20 years of financial and biopharma experience to the role. The company granted him an inducement stock option worth $2 million. Additionally, Sagimet approved inducement grants of stock options for four other newly-hired employees.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.